TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30376537

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK) at 2.5 μg·kg·min for 48 hours
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (LDK)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline at equivalent rate for 48 hours)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 91
Study: 30471966

Group type: EXPERIMENTAL
Intervention: Modified Ai Chi (50min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional aquatic therapy (50min)
Number of subjects: 18
Study: 27921201

Group type: EXPERIMENTAL
Intervention: Low frequency group (n = 37)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intermediate group (n = 17)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: High frequency group (n = 17)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low scorers cluster (n = 136)
Number of subjects: 37

Group type: COMPARATOR
Intervention: High scorers cluster (n = 26)
Number of subjects: 37
Study: 25459890

Group type: EXPERIMENTAL
Intervention: Isoallopregnanolone (ISO) administered in combination with Allopregnanolone (AP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Allopregnanolone (AP) alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoallopregnanolone (ISO) at a dose approximately half of AP
Number of subjects: 12
Study: 23412004

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 µg every 2 hours for up to 24 hours)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Oxytocin (10 IU infusion gradually increased)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 260
Study: 21600042

Group type: EXPERIMENTAL
Intervention: Internal fixation with additional bone graft substitute
Number of subjects: 39

Group type: COMPARATOR
Intervention: Internal fixation only
Number of subjects: 39
Study: 18633421

Group type: EXPERIMENTAL
Intervention: Maternal massage therapy (standard care plus maternal massage performed four times a day on the face and limbs)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Maternal massage therapy
Number of subjects: 104
Study: 16758751

Group type: EXPERIMENTAL
Intervention: peginterferon and ribavirin combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: two brands of peginterferon
Number of subjects: 0
Study: 15022864

Group type: EXPERIMENTAL
Intervention: Video-enhanced training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 99
Study: 11309871

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg intra-nasal midazolam
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg intra-nasal midazolam
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intra-nasal midazolam
Number of subjects: 38

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-fasting condition
Number of subjects: 38
Study: 9278832

Group type: EXPERIMENTAL
Intervention: Double lumen i.v. set (DLIS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single lumen i.v. set (SLIS)
Number of subjects: 50
Study: 8511732

Group type: EXPERIMENTAL
Intervention: Solenoid valve
Number of subjects: 12

Group type: COMPARATOR
Intervention: Weighted plunger
Number of subjects: 12
Study: 3549805

Group type: EXPERIMENTAL
Intervention: 2% minoxidil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3% minoxidil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (crossover to 3% minoxidil)
Number of subjects: 60
Study: 31652075

Group type: EXPERIMENTAL
Intervention: Verbal feedback
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Written feedback
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (routine method)
Number of subjects: 120
Study: 29309385

Group type: EXPERIMENTAL
Intervention: Freak Bar (FB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Traditional Barbell (TB)
Number of subjects: 10
Study: 27804269

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 100
Study: 24596968

Group type: EXPERIMENTAL
Intervention: Enjoy eating program (15 weeks)
Number of subjects: 20
Study: 24520741

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 100
Study: 21396089

Group type: EXPERIMENTAL
Intervention: Internet based self-help intervention for sub-clinical and mild PD
Number of subjects: 128

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 128
Study: 18500155

Group type: EXPERIMENTAL
Intervention: CHX‐T varnish (six applications every 15 days for 75 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo varnish (six applications every 15 days for 75 days)
Number of subjects: 57
Study: 16594879

Group type: EXPERIMENTAL
Intervention: Exercise program (12 weeks, 3 times per week, 30 minutes each session)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No intervention (control group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Social visit (control group 2)
Number of subjects: 75
Study: 15088900

Group type: EXPERIMENTAL
Intervention: NMP 22 Test
Number of subjects: 164

Group type: COMPARATOR
Intervention: Urine cytology
Number of subjects: 164
Study: 11120507

Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9361167

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (OM20)
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg once daily (OM10)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily (RAN)
Number of subjects: 994
Study: 8263387

Group type: EXPERIMENTAL
Intervention: Nasal pack retained for 24 hours
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Nasal pack retained for 48 hours
Number of subjects: 180

Group type: COMPARATOR
Intervention: No nasal pack
Number of subjects: 180
Study: 3725890

Group type: EXPERIMENTAL
Intervention: Diclofensine (50 mg single morning dose)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nomifensine (75-100 mg in two divided doses)
Number of subjects: 107
Study: 31060106

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) I (without disability)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) II (disabled only in some instrumental ADL)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL) III (disabled in some basic ADL)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes for all patients
Number of subjects: 84
Study: 29776750

Group type: EXPERIMENTAL
Intervention: Vi-DT (25 µg) administered at 0 and 4 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Typhim Vi® (first dose) and Vaxigrip® (second dose)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Vi-DT
Number of subjects: 144
Study: 27245206

Group type: EXPERIMENTAL
Intervention: Galactogogue containing silymarin-phosphatidylserine and galega, 5 g/day (galactogogue group, GG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo, 5 g of lactose per day (placebo group, PG)
Number of subjects: 100
Study: 25293975

Group type: EXPERIMENTAL
Intervention: Extended implementation strategy (visits from a guideline facilitator, stratification tools, feedback on guideline adherence)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual implementation
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Extended implementation strategy
Number of subjects: 1200
Study: 22284244

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet + Exercise (VLCD+E)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (Healthy Lean and Obese)
Number of subjects: 27
Study: 16019863

Group type: EXPERIMENTAL
Intervention: Fully Included (FI) students with CP
Number of subjects: 248

Group type: COMPARATOR
Intervention: Typical Students (TS)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Self-Contained (SC) students with CP
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Physical activity performance
Number of subjects: 248
Study: 12124548

Group type: EXPERIMENTAL
Intervention: Ulinastatin (5000 U/kg)
Number of subjects: 22
Study: 9846707

Group type: EXPERIMENTAL
Intervention: Oxytocin plus amniotomy
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Vaginal PGE2 2 mg, two doses at 6-hour intervals
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 320
Study: 7813723

Group type: EXPERIMENTAL
Intervention: Heparin injected into a central venous line 5 minutes before infrarenal aortic clamping (Group I)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heparin injected into the distal aneurysm immediately after infrarenal aortic clamping (Group II)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heparin injected into a central venous line immediately after infrarenal aortic clamping (Group III)
Number of subjects: 26
Study: 2676647

Group type: EXPERIMENTAL
Intervention: Salsalate 1.5 g twice daily
Number of subjects: 43

Group type: COMPARATOR
Intervention: Piroxicam 20 mg after evening meal
Number of subjects: 43
Study: 931293

Group type: EXPERIMENTAL
Intervention: Hearing aids equipped with directional microphones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hearing aids equipped with omni-directional microphones
Number of subjects: 0
Study: 29523560

Group type: EXPERIMENTAL
Intervention: Family group conferences
Number of subjects: 328
Study: 27560161

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol at 1000 IU/day for 2 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vitamin D levels in patients with acne
Number of subjects: 80
Study: 25057153

Group type: EXPERIMENTAL
Intervention: Overfeeding (140% of baseline energy requirements for 56 days)
Number of subjects: 0
Study: 22309784

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 600 mg gabapentin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 100
Study: 20502641

Group type: EXPERIMENTAL
Intervention: Oral polio vaccine (OPV) with BCG
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG only
Number of subjects: 0
Study: 17852673

Group type: EXPERIMENTAL
Intervention: Toe-clip pedals
Number of subjects: 11

Group type: COMPARATOR
Intervention: Flat pedals
Number of subjects: 11
Study: 16253622

Group type: EXPERIMENTAL
Intervention: Illness perceptions assessed within 24 hours of acute MI
Number of subjects: 194
Study: 12396332

Group type: EXPERIMENTAL
Intervention: Electric current perception threshold measurement
Number of subjects: 708
Study: 10430977

Group type: EXPERIMENTAL
Intervention: MMF 2 g
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: MMF 3 g
Number of subjects: 495

Group type: COMPARATOR
Intervention: AZA
Number of subjects: 495
Study: 7605950

Group type: EXPERIMENTAL
Intervention: Mild negative emotional changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild positive emotional changes
Number of subjects: 0
Study: 2132179

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg b.i.d. for 1 week followed by 40 mg b.i.d. for 3 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ketanserin and Placebo
Number of subjects: 221
Study: 620898

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (15 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control subjects (age-matched)
Number of subjects: 22
Study: 31887225

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Guselkumab
Number of subjects: 1027
Study: 31542049

Group type: EXPERIMENTAL
Intervention: Regular simple cubic configurations; magnetization oriented along a face or space diagonal of the cubic unit cell.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular simple cubic configurations; magnetization along the edge of the cubic unit cell.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body- and face-centered configurations; magnetization along a face or space diagonal of the unit cell.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized configurations; compressible systems.
Number of subjects: 0
Study: 28093243

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 26480547

Group type: COMPARATOR
Intervention: Western medication (estazolam 1mg before bed, oryzanol 20 mg three times a day) for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Acupuncture (at specific acupoints) for 4 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: Integrated acupuncture and medication (same as above) for 4 weeks
Number of subjects: 98
Study: 23633132

Group type: EXPERIMENTAL
Intervention: MitraClip device treatment for MR reduction
Number of subjects: 64
Study: 20697767

Group type: EXPERIMENTAL
Intervention: Intuitive strategies without WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intuitive strategies with WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytic strategies without WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analytic strategies with WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex GT with WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex GT without WM load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subjective expected utility measure
Number of subjects: 0
Study: 19857626

Group type: EXPERIMENTAL
Intervention: HAES group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Social support group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144

Group type: COMPARATOR
Intervention: HAES group vs Control group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Social support group vs Control group
Number of subjects: 144
Study: 17214093

Group type: EXPERIMENTAL
Intervention: Continuous combined estrogen (CEE + MPA)
Number of subjects: 7529

Group type: EXPERIMENTAL
Intervention: Continuous unopposed CEE
Number of subjects: 7529

Group type: EXPERIMENTAL
Intervention: Both estrogen treatments (CEE with or without MPA) pooled
Number of subjects: 7529

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 7529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7529
Study: 15342260

Group type: EXPERIMENTAL
Intervention: Learned encoding techniques acquired during nearly a thousand hours of practice memorizing the mathematical constant pi
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1
Study: 11316344

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite
Number of subjects: 996
Study: 9462188

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a median dose of 5 ppm for 72 hours
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no inhaled nitric oxide)
Number of subjects: 42
Study: 7875151

Group type: EXPERIMENTAL
Intervention: Ganciclovir plus GM‐CSF (1‐8 micrograms/kg daily subcutaneously)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ganciclovir alone
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Ganciclovir plus GM‐CSF
Number of subjects: 53
Study: 3344976

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 60
Study: 29476940

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 202

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 202
Study: 26847114

Group type: EXPERIMENTAL
Intervention: Intravenous esmolol for 24 hours
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 25594220

Group type: EXPERIMENTAL
Intervention: Miller laryngoscope (Mil)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope Pentax‐AWS Airway Scope (AWS‐N)
Number of subjects: 23
Study: 23084565

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg) followed by 300 IU rFSH in a GnRH antagonist protocol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard protocol for poor responders (short agonist-hMG)
Number of subjects: 43
Study: 20930611

Group type: EXPERIMENTAL
Intervention: Propofol-paravertebral anesthetic (PPA) technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced general anesthesia (GA)
Number of subjects: 40
Study: 18371596

Group type: EXPERIMENTAL
Intervention: Soda water (100 mL)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 95
Study: 16637756

Group type: EXPERIMENTAL
Intervention: Primed emotion words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Satiated emotion words
Number of subjects: 0
Study: 12792338

Group type: EXPERIMENTAL
Intervention: Transarticular screw fixation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Posterior cervical wiring and halo-vest immobilization
Number of subjects: 67
Study: 10802980

Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 58

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study: 8659596

Group type: EXPERIMENTAL
Intervention: Videokeratoscopic analysis of the peripheral recipient cornea
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Postoperative central corneal power
Number of subjects: 16
Study: 1985364

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 6345378

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nifedipine and Verapamil
Number of subjects: 103
Study: 31438268

Group type: EXPERIMENTAL
Intervention: Self-reported weight
Number of subjects: 0
Study: 30081337

Group type: EXPERIMENTAL
Intervention: School-based drug prevention program #Tamojunto
Number of subjects: 5028

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 5028
Study: 26856295

Group type: EXPERIMENTAL
Intervention: Sevoflurane (GS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol (GP)
Number of subjects: 20
Study: 23750966

Group type: EXPERIMENTAL
Intervention: Written text presented before speech
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written text presented after speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological correspondence between text and speech
Number of subjects: 0
Study: 22292487

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension (LE/T)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Loteprednol etabonate 0.5% (LE)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Tobramycin ophthalmic solution 0.3%
Number of subjects: 245

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 245
Study: 21060033

Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks
Number of subjects: 2046
Study: 17984242

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 15178207

Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 11432252

Group type: EXPERIMENTAL
Intervention: Internal thoracic artery graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venous grafts
Number of subjects: 0
Study: 9895187

Group type: COMPARATOR
Intervention: Electroacupuncture + placebo
Number of subjects: 270

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 270
Study: 8299330

Group type: EXPERIMENTAL
Intervention: 4 pints of Dioralyte (glucose and electrolyte solution)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 4 pints of half-strength Dioralyte
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 4 pints of water
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 6 pints of water
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: free fluids
Number of subjects: 197
Study: 2522117

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 14
Study: 7692934

Group type: EXPERIMENTAL
Intervention: Cytotoxic plus G-CSF mobilization
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cytotoxic mobilization
Number of subjects: 22
Study: 631687

Group type: EXPERIMENTAL
Intervention: Special institutions for mentally abnormal offenders
Number of subjects: 348
Study: 31536007

Group type: EXPERIMENTAL
Intervention: CRT+MIT
Number of subjects: 34

Group type: COMPARATOR
Intervention: CRT
Number of subjects: 34
Study: 27806647

Group type: EXPERIMENTAL
Intervention: 200 mg slow-release L-cysteine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 25805886

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) program utilizing active-play video games (Xbox 360 Kinect) and traditional AE equipment for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard psychiatric treatment (treatment as usual; TAU)
Number of subjects: 33
Study: 23790994

Group type: EXPERIMENTAL
Intervention: Enhanced group (received narratives and peer support for CRC screening in online forums)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Enhanced group
Number of subjects: 306

Group type: COMPARATOR
Intervention: Basic group (received education only)
Number of subjects: 306
Study: 21453351

Group type: EXPERIMENTAL
Intervention: α-blockers (tamsulosin or alfuzosin)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 461
Study: 19148579

Group type: EXPERIMENTAL
Intervention: Intensified MAID (5 cycles, doses 20-33% higher per cycle)
Number of subjects: 162

Group type: COMPARATOR
Intervention: MAID (6 cycles: 60, 7,500, 900 mg/m(2) for doxorubicin, ifosfamide and dacarbazine)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Intensified MAID
Number of subjects: 162

Group type: COMPARATOR
Intervention: MAID
Number of subjects: 162